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doi:10.1016/j.ejvs.2010.11.025Abstract Objectives: To compare the outcomes of femoropopliteal percutaneous translum-
inal angioplasty (PTA) and bypass surgery for critical limb ischaemia (CLI).
Design: The study is retrospective in nature.
Materials and methods: This study included 858 consecutive patients, who underwent femor-
opopliteal revascularisation for CLI at Helsinki University Central Hospital during 2000e2007.
As many as 517 patients (60%) underwent PTA and 341 (40%) bypass surgery. Propensity score
analysis was used for risk adjustment in multivariable analysis and for one-to-one matching.
Results: In the overall series, PTA had poorer long-term results than bypass (5-year leg salvage,
78.2% vs. 91.8%, p < 0.0001; survival 49.2% vs. 57.1%, p Z 0.048; amputation-free survival,
42.0% vs. 53.7%, p Z 0.003; freedom from surgical re-intervention 86.2% vs. 94.3%,
p < 0.0001).
When treatment method was adjusted for propensity score as well as in the propensity
score-matched pairs, leg salvage and freedom from surgical re-intervention were worse after
PTA than after bypass (among the 241 propensity score-matched pairs, 74.3% vs. 88.2%,
p Z 0.031, and 86.1% vs. 89.8%, p Z 0.025, respectively). Differences in survival, amputa-
tion-free survival and freedom from any re-intervention were not observed.
Conclusions: In CLI patients, femoropopliteal PTA seems to be associated with poorer long-
term leg salvage and freedom from surgical re-intervention than bypass surgery. However,
the treatment method did not affect long-term amputation-free survival.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.of Vascular Surgery, Helsinki University Central Hospital, POB 340, 00029 Helsinki, Finland. Tel.: þ358
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Infrainguinal bypass surgery has traditionally been consid-
ered the approach of choice to treat critical limb ischaemia
(CLI) to avoid major amputation. However, there are
increasing data on the efficacy of endovascular revascu-
larisation procedures to achieve good leg salvage rates.1e3
Indeed, the use of endovascular procedures has rapidly
increased during the last decade.4 As yet, there is only one
large, randomised controlled trial comparing the two
treatment methods, the Bypass or Angioplasty for Severe
Ischaemic Leg (BASIL) e Trial.5 The comparison of surgical
and endovascular techniques in randomised controlled
trials is difficult due to problems of forming comparable
groups. To overcome this issue, we have analysed our long-
term results in the treatment of femoropopliteal occlusive
lesions in CLI patients, by adjusting the differences
between the two treatment arms using propensity score
analysis.6,7
Material and Methods
A total of 2054 patients with CLI underwent lower-limb
revascularisation at the Department of Vascular Surgery,
Helsinki University Central Hospital, between 2000 and
2007. Unilateral, femoropopliteal revascularisation was
performed in 858 patients, of whom 517 patients (60.3%)
underwent percutaneous transluminal angioplasty (PTA)
and 341 (39.7%) bypass surgery. No other arterial segments
were treated simultaneously. All cases and angiographies
were reviewed and discussed for decision making at the
daily integrated vascular meetings of vascular surgeons and
interventional radiologists. Clinical characteristics, opera-
tive data and immediate postoperative outcome data of
these patients were prospectively collected in our institu-
tional database and scrutinised retrospectively (Table 1).
Dates of death were retrieved from the Finnish national
registry (Statistics Finland). Data on late, major lower
amputation and re-interventions have been completed
retrospectively from files of the National Research and
Development Centre for Health and Welfare.
The study protocol was approved by the Institutional
Review Board of the Helsinki University Central Hospital,
Finland (Department of Surgery).
Preoperative estimated glomerular filtration rate (eGFR)
was calculated according to the Modification of Diet in
Renal Disease study equation.8 Severity of renal failure was
classified according to the chronic kidney disease (CKD)
classification.8
Endovascular revascularisation
Balloon angioplasty was the method of choice for endo-
vascular approach. Stents were placed selectively in cases
in which there was a flow-limiting dissection or a significant
residual stenosis after balloon angioplasty. A stent was
placed in 3% of the primary interventions. Intra-arterial
heparin (5000 IU) was routinely administered just before
the endovascular procedure.
After successful endovascular intervention, patients
received 300 mg of clopidogrel orally and were maintainedon 75 mg day1 for at least 1 month, except for those on
continued anticoagulation already before revascularisa-
tion. In addition, the patients were indefinitely put on
100 mg aspirin orally. This medication scheme became
routine in 2001; before that, patients were put only on
aspirin. Routine follow-up included one clinical examina-
tion and an ankleebrachial index (ABI) measurement at 1
month after the procedure. Duplex Doppler (DD) ultrasound
scan was done when needed.
Surgical revascularisation
Non-reversed vein grafts weremostly used. A prosthetic graft
had to be used in 21.3% of the patients because of the lack of
suitable veins. The patients received low-molecular-weight
heparinduring theirpostoperativehospital stay, inaddition to
100 mg of aspirin orally, which was continued indefinitely.
Routine surveillance included a clinical examination, ABI
measurement and a DD scan at 1, 6 and 12 months.
Angiographic status of runoff arteries
Periprocedural angiographies were retrospectively
reviewed by three authors (M.V., K.H. and M.K.). The
angiographic status of the runoff vessels was quantified at
the site of angioplasty/distal anastomosis downwards, and
the runoff score was calculated according to the Society for
Vascular Surgery/International Society for Cardiovascular
Surgery (SVS/ISCVS) criteria.9
Outcome end points
Overall survival, major lower-limb amputation, (major)
amputation-free survival, freedom from any further re-
intervention (including all open and endovascular re-inter-
ventions done to maintain the original revascularisation and
redo procedures done due to occlusion of the original
revascularisation) and freedom from surgical re-interven-
tion (redo bypass, that is, bypass that comprises more than
half of the graft) were considered the main outcome
measures of this study.
Statistical analysis
Statistical analysis was performed using Statistical
Package for Social Sciences (SPSS) statistical software
(SPSS v. 16.0.1, SPSS Inc., Chicago, IL, USA). Continuous
variables are reported as the mean  standard deviation.
Pearson’s chi-square test, Fisher’s exact test and the
ManneWhitney test were used for univariate analysis.
Logistic regression with backward selection was per-
formed to calculate the risk of these patients to be
included either in the angioplasty or bypass surgery group.
HosmereLemeshow’s test was used to assess the regres-
sion model fit. Variables listed in Table 1 and having
a p < 0.2 in univariate analysis were included into the
regression model. Receiver operating characteristic (ROC)
curve analysis was used to estimate the area under the
curve of the model predicting the probability of being
included into the angioplasty or bypass surgery group. The
calculated propensity score was employed for one-to-one
Table 1 Baseline characteristics and operative data on patients who underwent femoropopliteal bypass surgery and percu-
taneous transluminal angioplasty (PTA) for critical limb ischaemia. Data are reported for the overall population and for one-to-
one propensity score-matched pairs.
Overall series Propensity score-matched pairs
PTA Bypass p-value PTA Bypass p-value
517 patients (%) 341 patients (%) 241 patients (%) 241 patients (%)
Age (years)* 74.5  11.8 71.5  10.4 <0.0001 74.3  11.8 72.7  10.2 0.06
Females* 201 (38.9) 173 (50.7) 0.001 111 (46.1) 110 (45.6) 0.93
Pulmonary disease* 78 (15.1) 73 (21.4) 0.017 40 (16.6) 39 (16.2) 0.90
Diabetes* 301 (58.2) 137 (40.2) <0.0001 100 (41.5) 102 (42.3) 0.85
Hypertension 394 (76.4) 237 (69.9) 0.036 179 (74.3) 174 (72.5) 0.66
Coronary artery disease 318 (61.5) 207 (60.9) 0.85 145 (60.2) 149 (61.8) 0.71
Cerebrovascular disease* 110 (21.3) 45 (13.4) 0.003 39 (16.2) 36 (14.9) 0.71
Smoking habit* 122 (23.6) 127 (37.7) <0.0001 62 (25.7) 79 (32.9) 0.08
Previous lower-limb
revascularisation*
61 (11.8) 56 (16.4) 0.053 22 (9.1) 34 (14.1) 0.09
Previous revascularisation
on the same segment
45 (8.7) 30 (8.8) 0.96 16 (6.6) 16 (6.6) 1.00
Serum creatinine (micromol/l) 145  149 106  90 <0.0001 108  86 107  85 0.88
eGFR (mL/min/1.73 m2) 62  34 75  34 <0.0001 71  32 72  35 0.88
CKD classes* <0.0001 1.00
1 95 (18.4) 93 (27.3) 60 (24.9) 59 (24.5)
2 159 (30.8) 136 (39.9) 91 (37.8) 89 (36.9)
3 175 (33.8) 87 (25.5) 72 (29.9) 73 (30.3)
4 42 (8.1) 15 (4.4) 11 (4.6) 13 (5.4)
5 46 (8.9) 10 (2.9) 7 (2.9) 7 (2.9)
Indication for revascularisation <0.0001 0.25
Rest pain 103 (19.9) 149 (43.7) 63 (26.1) 64 (26.6)
Ulcer* 334 (64.6) 171 (50.1) 148 (61.4) 158 (65.6)
Gangrene* 80 (15.5) 21 (6.2) 30 (12.4) 19 (7.9)
Angiographic score* 6.7  2.3 5.5  2.3 <0.0001 6.2  2.2 5.9  2.2 0.80
Target vessel patent downward
to the pedal arteries*
276 (53.4) 257 (75.4) <0.0001 164 (68.0) 165 (68.5) 0.92
Most distal target artery
Below-the-knee
popliteal artery
91 (17.6) 233 (68.3) <0.0001 44 (18.3) 165 (68.5) <0.0001
Bypass graft e e
Vein graft e 263 (78.7) e 194 (80.5)
Prosthetic graft e 71 (21.3) e 47 (19.5)
PTA: percutaneous transluminal angioplasty, CKD classes: Chronic kidney disease classes (class 1 (normal): eGFR > 90 ml/min/1.73 m2;
class 2 (mild): eGFR 60e89 ml/min/1.73 m2; class 3 (moderate): eGFR 30e59 ml/min/1.73 m2; class 4 (severe); eGFR 15e29 ml/min/
1.73 m2, class 5 (kidney failure): eGFR < 15 ml/min/1.73 m2.); eGFR: estimated glomerular filtration rate (eGFR (ml/min/
1.73 m2) Z 186  (serum creatinine (mg/dl))1.154  (age)0.203  0.742 (if the subject is female)  1.212 (if the subject is black));
*: variable included into regression model for estimation of the propensity score.
380 M. Korhonen et al.matching as well as to adjust for other variables in esti-
mating their impact on the postoperative outcome. We did
not performed analysis in propensity score percentiles
because of the relatively small number of patients. One-
to-one propensity score matching between study groups
was done according to a difference in the propensity
score < 0.005. Cox regression with the help of backward
selection was used to adjust the effect of treatment
method for propensity score as well as other variables in
evaluating continuous outcome end points. Long-term
outcome was assessed by the KaplaneMeier’s method with
the log-rank test and the Cox regression method. Outcome
in the propensity matched pairs was evaluated by
KaplaneMeier’s methods as well as the Cox regressionmethod. In the latter, the treatment method was
adjusted, as suggested by Austin,10 for other important
variables, that is, age, gender, diabetes, presence of foot
ulcer/gangrene, coronary artery disease, eGFR and patent
target vessel down to the pedal arteries. A p < 0.05 was
considered statistically significant.Results
The mean length of the follow-up was 2.6  2.2 years. Leg
salvage rates of the overall population at 30-day, 1-year,
3-year and 5-year intervals were 98.0%, 90.1%, 85.9% and
83.3%, respectively (standard error (SE) < 0.018). At the
Figure 1 Flow-chart summarising need of intervention and amputation-free survival after femoropopliteal percutaneous
transluminal angioplasty and bypass surgery for critical limb ischaemia in the overall population.
Angioplasty vs. Bypass Surgery for CLI 381same intervals, survival rates were 96.8%, 78.2%, 61.2% and
52.2%, respectively (SE < 0.021) and amputation-free
survival rates were 94.4%, 73.9%, 55.6% and 46.3%,
respectively (SE < 0.022). Fig. 1 summarises the need for
re-interventions and amputation-free survival after PTA
and bypass surgery in the overall population.
Results of angioplasty vs. bypass surgery in the
overall series
PTA had poorer long-term results than bypass surgery (Table
2). There was a significant difference at 5 years in survival
(49.2% vs. 57.1%, p Z 0.048), amputation-free survivalTable 2 KaplaneMeier’s estimates of early and late outcome in
reported in parentheses.
30-day 1-year
Overall survival
PTA 94.9% (486) 75.7% (346)
Bypass surgery 97.6% (330) 82.2% (229)
Leg salvage
PTA 96.8% (473) 87.0% (319)
Bypass surgery 99.7% (329) 95.0% (223)
Amputation-free survival
PTA 92.4% (473) 70.0% (319)
Bypass surgery 97.4% (329) 79.9% (223)
Freedom from any re-intervention
PTA 93.9% (457) 76.4% (271)
Bypass surgery 94.7% (309) 84.1% (192)
Freedom from surgical re-intervention
PTA 93.7% (456) 86.3% (303)
Bypass surgery 99.4% (329) 96.0% (220)(42.0% vs. 53.7%, pZ 0.003) (Fig. 2(a)) and leg salvage (78.2%
vs. 91.8%, p < 0.0001) (Fig. 3(a)). Freedom from any re-
intervention did not differ between the study groups (at 5
years: PTA 77.3% vs. bypass 74.4%, p Z 0.47), whereas
freedom from surgical re-intervention was significantly
worse after PTA (at 5 years: 86.2% vs. 94.3%, p < 0.0001).
Propensity score analysis
Patients who underwent PTA had significantly more co-
morbidities, such as diabetes and decreased eGFR, and poorer
runoff. As the study groups differedmarkedly from each other,
wecalculated thepropensity score toestimate the risk of thesethe overall series. Number of patients entering intervals are
2-year 3-year 4-year 5-year p-value
0.048
67.1% (266) 58.9% (204) 52.4% (153) 49.2% (111)
76.0% (163) 65.0% (126) 59.7% (91) 57.1% (57)
<0.0001
84.0% (241) 82.1% (183) 79.7% (136) 78.2% (96)
92.5% (152) 91.8% (117) 91.8% (85) 91.8% (54)
0.003
60.2% (241) 52.1% (183) 45.5% (136) 42.0% (97)
72.6% (152) 61.0% (117) 56.3% (85) 53.7% (54)
0.30
75.1% (214) 74.7% (169) 74.7% (126) 75.2% (95)
79.7% (125) 78.3% (95) 75.4% (66) 75.4% (39)
<0.0001
85.7% (233) 85.7% (182) 85.7% (136) 85.7% (101)
95.0% (152) 94.3% (118) 91.5% (83) 91.5% (52)
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Figure 2 Amputation-free survival after femoropopliteal
percutaneous transluminal angioplasty and bypass surgery for
critical limb ischaemia a) in the overall series and b) in 241
propensity score-matched pairs.
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Figure 3 Leg salvage after femoropopliteal percutaneous
transluminal angioplasty and bypass surgery for critical limb
ischaemia a) in the overall series and b) in 241 propensity
score-matched pairs.
382 M. Korhonen et al.patients to undergo either PTA or bypass surgery. Variables
included in the logistic regression model for calculation of
propensity score are listed in Table 1. Pulmonary disease
(b-coefficient 0.407), female gender (b-coefficient 0.466),
diabetes (b-coefficient 0.561), cerebrovascular disease
(b-coefficient0.561), eGFR (b-coefficient0.210), leg status
(rest pain vs. ulcer or gangrene, b-coefficient 1.048) and
patent target vessel down to the pedal artery (b-coefficient
1.1001) were used as independent predictors for assigning
patients with CLI to the femoropopliteal PTA or bypass surgery
group (constant b-coefficient 0.216, HosmereLemeshow’s test
pZ 0.424). The obtained propensity score had an area under
the ROC curve of 0.73 (95% confidence interval (CI) 0.70e0.76,
SE 0.017, p< 0.0001).
Results of PTA vs. bypass surgery according to
propensity score analysis
In the overall series, when treatment method was adjusted
for propensity score, PTA was associated with significantly
poorer leg salvage (p Z 0.020, risk ratio (RR) 1.81, 95%CI
1.10e2.97) and freedom from surgical re-intervention
(p Z 0.002, RR 2.45, 95%CI 1.40e4.29). When adjusted for
propensity score, survival (p Z 0.34), amputation-freesurvival (p Z 0.89) and freedom from any re-intervention
procedure (p Z 0.29) did not statistically significantly
differ between the study groups.
One-to-one propensity score matching provided 241
pairs of patients, who underwent either PTA or bypass
surgery (Table 1). Amputation-free survival was similar in
propensity score-matched pairs (Fig. 2(b)). During the 5-
year follow-up, bypass surgery was associated with signifi-
cantly better leg salvage in the matched pairs analysis
(88.2% vs. 74.3%, log-rank: p Z 0.031; adjusted RR 0.57,
95%CI 0.34e0.95, p Z 0.003) (Fig. 3(b)) and freedom from
surgical re-intervention (89.8% vs. 86.1%, log-rank:
p Z 0.025; adjusted RR 0.48, 95%CI 0.26e0.99, p Z 0.02)
(Table 3). However, bypass surgery and PTA achieved
similar rates of survival (52.5% vs. 53.4%, log-rank:
p Z 0.85; adjusted p Z 0.28), amputation-free survival
(47.6% vs. 44.6%, log-rank: p Z 0.54; adjusted p Z 0.96)
and freedom from any re-intervention (76.5% vs. 74.5%, log-
rank: p Z 0.13; adjusted p Z 0.08).
Discussion
Comparison of endovascular and surgical revascularisation
in CLI is difficult because patient groups tend to differ in
Table 3 KaplaneMeier’s estimates of early and late outcome in 241 propensity score-matched pairs. Number of patients
entering intervals are reported in parentheses.
30-day 1-year 2-year 3-year 4-year 5-year p-value
Overall survival 0.85
PTA 95.0% (226) 76.6% (162) 70.6% (135) 63.2% (101) 56.0% (78) 53.4% (56)
Bypass surgery 97.9% (234) 80.0% (156) 73.4% (106) 62.6% (85) 56.0% (61) 52.5% (39)
Leg salvage 0.031
PTA 96.6% (221) 87.7% (150) 84.7% (125) 81.8% (95) 80.0% (71) 77.3% (48)
Bypass surgery 99.6% (233) 92.9% (150) 89.2% (99) 88.2% (77) 88.2% (55) 88.2% (36)
Amputation-free survival 0.54
PTA 92.9% (221) 71.0% (150) 63.7% (125) 56.1% (94) 48.7% (71) 44.6% (48)
Bypass surgery 97.5% (233) 76.8% (150) 68.5% (99) 57.0% (77) 51.1% (55) 47.6% (36)
Freedom from any re-intervention 0.13
PTA 92.4% (209) 75.7% (128) 74.5% (108) 74.5% (83) 74.5% (65) 74.5% (48)
Bypass surgery 96.7% (227) 86.5% (135) 82.8% (86) 80.7% (67) 76.5% (46) 76.5% (29)
Freedom from surgical re-intervention 0.025
PTA 92.4% (209) 86.7% (144) 86.1% (119) 86.1% (91) 86.1% (71) 86.1% (52)
Bypass surgery 99.2% (233) 95.6% (149) 94.9% (100) 93.9% (79) 89.8% (54) 89.8% (35)
Angioplasty vs. Bypass Surgery for CLI 383terms of risk factors as well as arterial lesions requiring
treatment. In non-randomised observational studies,
investigators have no control over treatment assignment.
This difficulty may be partially avoided if information of
measured covariates, that is, risk factors, is incorporated
into the study design. Propensity score is a measure of the
likelihood that a patient would have been treated using
their covariate scores. Propensity scores are used for
reducing bias and increasing precision by making adjust-
ments to risk factors prior or while calculating the effect of
the treatment.7 Herein, we used the propensity score for
regression adjustment and for matching. Importantly, we
have adjusted the treatment method for the most relevant
covariates also in the one-to-one propensity matched pairs
analysis as suggested by Austin.10 Yet, we were unable to
include the characteristics of treated lesions as an unam-
biguous covariate. Indeed, The Inter-Society Consensus for
Management of PAD (TASC II) classification for femo-
ropopliteal lesions allows rather wide individual interpre-
tations, and the common use of this classification as a basis
for reporting outcomes can therefore be questioned.11 The
lesions treated by angioplasty were probably shorter and
less severe than those in the bypass surgery group. As
previous randomised trials have demonstrated, only 4e29%
of the lesions have been considered equally well treatable
by either method,5,12 which worsens the generalisability of
the findings of randomised controlled trials in CLI. On the
other hand, the strength of a registry based study is the
large coverage of the patients in daily practice.
Amputation-free survival is considered the most impor-
tant outcome end point in the treatment of CLI.13 After
adjusting the groups by propensity score, no significant
difference in the amputation-free survival between the
treatments was observed, but bypass surgery was associated
with significantly better long-term leg salvage. Themortality
of CLI patients is very high due to the generalised nature of
their atherosclerosis. Indeed, the high mortality might have
masked the effect of the better long-term leg salvage after
bypass on amputation-free survival.A similar difference in leg salvage between PTA and
bypass was not observed in our previous study on revascu-
larisation of infrapopliteal arteries with or without simul-
taneous treatment of femoropopliteal segment lesions.14
PTA was associated with better limb salvage in a subgroup
analysis on patients who underwent isolated infrapopliteal
PTA, that is, in patients free of marked femoropopliteal
disease. The results of that study as well as of the present
study suggest that bypass surgery may do better in the long-
term in terms of leg salvage, when significant femo-
ropopliteal arterial lesions are treated. Further, in the
intention-to-treat analysis of the BASIL trial, for those
patients surviving more than 2 years after the random-
isation, the bypass surgery’s first strategy was associated
with a significant increase in subsequent overall survival
and a trend towards improved amputation-free survival.15
This further supports the long-term benefits of bypass
surgery over PTA in the treatment of CLI, at least in
patients with longevity exceeding 2 years.
In the overall series as well as in the propensity score-
matched pairs, the rate of surgical re-intervention was
significantly higher after PTA than bypass surgery. This is
highly due to our general practice: if CLI symptoms do not
relieve and the endovascularly treated segment has
occluded, threshold for surgical re-intervention is relatively
low. Redo-PTA is done only in cases with mild-to-moderate
recurrent symptoms.
However, freedom from any re-intervention was the
same after both treatment methods. Most probably, our
active surveillance policy on venous grafts and the
predominantly endovascular treatment of graft stenoses
were the reasons for equal rates of any re-interventions
between the treatment groups.
A possible limitation of the current study is the differ-
ence in the routine surveillance protocol of the two
revascularisation strategies during the study period. All
patients were followed until their symptoms subsided and/
or wounds healed. Routine clinical examination and ABI
measurements were done up to 4 weeks postprocedurally
384 M. Korhonen et al.for the PTA group, whereas they were done up to 12 months
alongside with DD for the bypass surgery group. Thus, it
might be that first signs of restenosis were found earlier in
the bypass surgery group. No resources were directed
formerly on routine long-term follow-up for the PTA
patients because of the lack of evidence of its benefits
compared with the scheme we were following. On the other
hand, at that time, studies on benefits of routine surveil-
lance of vein grafts had been published.16 Even though
there is still today no consensus on how endovascularly
treated patients should best be followed, we have recently
changed our surveillance protocols so that they are now
identical for both, surgical and endovascular revascular-
isation strategies.
Another limitation is the nature of registry based
studies, that is, concern regarding data validity and
completeness. We have made an effort to minimise these
limitations. Our vascular registry includes all patients who
have undergone any revascularisation, endovascular or
surgical. The completeness of the registry data has been
checked against hospital registries and missing data have
been entered into the registry afterwards. The key
outcome end points were double-checked against official
national registries. Yet, no registry is immune from omis-
sions and differences in the interpretation of the data.17,18
Conclusions
About half of the patients with CLI were alive and had not
sustained major amputation 5 years after revascularisation,
irrespective of the mode of treatment. This underlines the
malign nature of atherosclerotic disease in these patients.
However, leg salvage and freedom from surgical re-inter-
vention were significantly better after bypass surgery, but
amputation-free survival was similar in the study group
after risk adjustment. This suggests that when technically
feasible, PTA can be considered a valid alternative first
strategy to bypass surgery in patients with CLI and femo-
ropopliteal disease. Bypass surgery could likely be consid-
ered as a better alternative in patients with probable
longevity.
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